<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mehta, Michael D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The future of nanomedicine looks promising, but only if we learn from the past</style></title><secondary-title><style face="normal" font="default" size="100%">Health Law Review</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Winter 2004</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.law.ualberta.ca/centres/hli/userfiles/13-1-03_Mehta.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">16-18</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Article draws on the history of the public acceptance of nuclear medicine and biotechnology to suggest ways in which public trust can be built for the medical use of nanotechnology. The author recommends a free and open discussion of the potential risks of nanomedicine, the need for regulatory bodies to investigate how current oversight may need to be changed in regard to nanomedicine, and investigation of how the benefits of these new technologies will be distributed among richer and poorer populations.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type></record></records></xml>